Figure 1 Overview of biosimilar product development

Slides:

Advertisements

Similar presentations

1. Within a few years, more than half of newly approved medicines will be biopharmaceuticals. To ensure safety and efficacy, the FDA created a daunting.

Advertisements

Analytical Similarity Assessment: Practical Challenges and Statistical Perspectives Richard Montes, Ph.D. Hospira, a Pfizer company Biosimilars Pharmaceutical.

Mammalian Cell Expression Profacgen. Mammalian cell expression systems are the best choice for the production of eukaryotic proteins, especially when.

Introduction to Biosimilars

of different experimental arthritis models

Figure 3 Connexins in cartilage

Figure 2 A timeline summarizing the development of diagnostic tools in rheumatology Figure 2 | A timeline summarizing the development of diagnostic tools.

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Figure 1 Grip strength across the lifecourse

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Cellular processes involved in cancer development

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Factors underlying metabolic alterations in osteoarthritis

Figure 1 Induction of immune tolerance

Biosimilars in RA: A Blessing or a Curse?

Figure 2 Risk factors for sarcopenia

Nat. Rev. Urol. doi: /nrurol

Figure 2 Heat map of targeted therapies in autoimmune diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Targeted versus untargeted metabolomics approaches

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Simplified EULAR and GRAPPA

Figure 2 Simplified EULAR and GRAPPA

Figure 3 Transcriptome studies performed in the target

Figure 1 Biosimilar development process

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Location of HLA variants known to be associated

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Diagnostic tiers of Parkinson disease as single disease

Figure 3 Defects in the T cell receptor signalling pathway

Figure 3 Endogenous repair of double-strand DNA breaks

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 4 Post-test probability as a function of pre-test

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Overlap of associated loci among five rheumatic diseases

Figure 2 Interaction effects between heterozygous HLA‑DRB1

Figure 1 The two-compartment model of body composition

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Multi-hit model for autoimmune diseases

Figure 1 Simplified EULAR and GRAPPA

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Research advances in osteoarthritis management

Figure 2 Emerging hallmarks of T cells in rheumatoid arthritis

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Treat to target, remission and low disease activity in SLE

Figure 1 Biospecimen handling pipeline

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Clinical aspects of LGMD subtypes

Figure 1 Principles for the diagnosis and management of osteoarthritis

Nat. Rev. Urol. doi: /nrurol

Figure 1 Transmission of pain by NGF

Figure 2 A model of TNFR–complex I signalling

Interaction networks of the regulated phosphoproteins.

Nat. Rev. Rheumatol. doi: /nrrheum

Figure Overview.

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Chronic inflammation and DNA damage in people with SLE

Figure 1 Overall worldwide prevalence ranges for SLE

Figure 1 Differential effects of bone-forming agents on bone surfaces

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Overview of the imaging biomarker roadmap

A Primer on Biosimilars

Nat. Rev. Rheumatol. doi: /nrrheum

Presentation transcript:

Figure 1 Overview of biosimilar product development Figure 1 | Overview of biosimilar product development. Biosimilar product development should start with searches of publicly available information on the reference product, its target and the known biology. The protein structure, post-translational modifications and biological activity of the reference product should be analysed by the biosimilar sponsor to determine the product profile. Development of the expression system (expression construct and host cell line) and the manufacturing process should be extensive to provide a firm foundation for demonstration of biosimilarity. If FDA categorization of a proposed biosimilar product of 'highly similar' can be made on the basis of these data early in development, a selective and targeted approach to clinical testing might be possible. Nikolov, N. P. & Shapiro, M. A. (2016) An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2016.204